Supplementary Figure. Trends in Estimated Proportions of SARS-CoV-2 Reverse Transcription–Polymerase Chain Reaction Test Results With S-Gene Target Presence and Variant Proportions and Nowcast Projections FromGenomic Surveillance Classified by S-Gene Target Presence or S-Gene Target Failure — United States, September 27, 2023–January 20, 2024

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.

i

Supplementary Figure. Trends in Estimated Proportions of SARS-CoV-2 Reverse Transcription–Polymerase Chain Reaction Test Results With S-Gene Target Presence and Variant Proportions and Nowcast Projections FromGenomic Surveillance Classified by S-Gene Target Presence or S-Gene Target Failure — United States, September 27, 2023–January 20, 2024

02/01/2024
By Centers for Disease Control and Prevention (U.S.)
Source: MMWR: Morbidity and Mortality Weekly Report 2024; v. 73, no. 4
Series: Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

English

Details Related Documents You May Also Like

Details:

Alternative Title:

Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributableto Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024: Supplementary Figure. Trends in Estimated Proportions of SARS-CoV-2 Reverse Transcription–Polymerase Chain Reaction Test Results With S-Gene Target Presence and Variant Proportions and Nowcast Projections FromGenomic Surveillance Classified by S-Gene Target Presence or S-Gene Target Failure — United States, September 27, 2023–January 20, 2024
Corporate Authors:

Centers for Disease Control and Prevention (U.S.)
Source:

MMWR: Morbidity and Mortality Weekly Report 2024; v. 73, no. 4
Series:

Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
ISSN:

0149-2195 (print);1545-861X (digital);
Document Type:

Journal Article
Place as Subject:

United States
Pages in Document:

1 pdf page
Volume:

73
Issue:

4
Collection(s):

Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:

[+]

urn:sha-512:0155fa3dd6df566ec761aae7676268f59f7eb6100ce296023f5347cf5c74dea298fd358a1cfeba96ce5e54c652994d459c4c0919fe3221816d6f0c284c0135ff
Download URL:

https://stacks.cdc.gov/view/cdc/145936/cdc_145936_DS1.pdf
File Type:

[PDF-278.94 KB]